Revolution appoints J&J's Elizabeth McKee Anderson to board
This article was originally published in Scrip
Revolution Medicines, a company developing innovative drugs by redesigning natural compounds, has named Elizabeth McKee Anderson, former worldwide vice-president of infectious diseases and vaccines at Janssen Pharmaceuticals, to its board of directors. Previously Ms Anderson has held several leadership positions within Johnson & Johnson, including vice-president of global biologics strategic marketing at Centocor, an operating company of Johnson & Johnson.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.